Why experts are criticizing FDA's approach to some neurological drugs
Some experts fear the FDA's accelerated approval process for neurological disease treatments greenlights clinically promising but unproven drugs that can result in giving patients false hope. Host Kelly Hooper talks with POLITICO health care reporter Katherine Ellen Foley about how the FDA is balancing those concerns against the needs of patients.
Audio is streamed directly from the publisher (traffic.megaphone.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Some experts fear the FDA's accelerated approval process for neurological disease treatments greenlights clinically promising but unproven drugs that can result in giving patients false hope. Host Kelly Hooper talks with POLITICO health care reporter Katherine Ellen Foley about how the FDA is balancing those concerns against the needs of patients.
Learn more about your ad choices. Visit megaphone.fm/adchoices